Yin Xidie, Zhao Yiting, Zhou Liyuan, Liu Xiaojing, Yan Yu, Cao Zhi, Shen Shu Zhan, Chang Qihang, Cao Yajing, Wang Xiuli, Wang Peiru
Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Acta Derm Venereol. 2025 Sep 4;105:adv43615. doi: 10.2340/actadv.v105.43615.
COVID-19 can affect the skin, with rosacea flare-ups reported after infection or vaccination. This study compared rosacea patients with and without post-COVID-19 exacerbation to identify contributing factors. A customized electronic questionnaire was administered to rosacea patients, gathering COVID-19 infection/vaccination status, demographics, and rosacea features. Participants were classified by post-COVID-19 rosacea exacerbation vs none. Multivariable logistic regression identified risk factors. Finally, a total of 104 patients were analysed; 15.4% experienced rosacea exacerbation after COVID-19 vaccination and 28.8% after infection. Comorbidities such as metabolic diseases or allergic diseases were associated with a higher risk of rosacea exacerbation after vaccination or infection (OR = 11.083, 95% CI: 1.136-108.135). Burning and stinging symptoms predicted higher exacerbation risk after vaccination (OR = 8.978, 95% CI 1.968-40.969). Papulopustular rosacea was associated with lower risk (OR = 0.276, 95% CI: 0.066-1.160). Higher body mass index (BMI) was associated with lower exacerbation risk after vaccination (OR = 0.646, 95% CI 0.450-0.928) and infection (OR = 0.731, 95% CI: 0.572-0.933). Frequent rosacea episodes increased exacerbation risk after infection (OR = 8.288, 95% CI: 2.044-33.608). In conclusion, lower BMI was associated with higher risk of rosacea exacerbation after COVID-19 vaccination or infection. Patients with burning and stinging symptoms or a non-papulopustular subtype were more likely to experience exacerbation after vaccination.
新冠病毒病（COVID-19）可影响皮肤，有报告称感染或接种疫苗后会出现玫瑰痤疮发作。本研究比较了有和没有新冠后玫瑰痤疮加重的患者，以确定相关因素。对玫瑰痤疮患者进行了定制的电子问卷调查，收集新冠病毒感染/疫苗接种状况、人口统计学信息和玫瑰痤疮特征。参与者按新冠后玫瑰痤疮是否加重进行分类。多变量逻辑回归确定了风险因素。最后，共分析了104例患者；15.4%在接种新冠疫苗后出现玫瑰痤疮加重，28.8%在感染后出现加重。代谢疾病或过敏性疾病等合并症与接种疫苗或感染后玫瑰痤疮加重的风险较高相关（比值比[OR]=11.083，95%置信区间[CI]：1.136-108.135）。灼痛和刺痛症状预示接种疫苗后加重风险较高（OR=8.978，95%CI 1.968-40.969）。丘疹脓疱型玫瑰痤疮与较低风险相关（OR=0.276，95%CI：0.066-1.160）。较高的体重指数（BMI）与接种疫苗（OR=0.646，95%CI 0.450-0.928）和感染（OR=0.731，95%CI：0.572-0.933）后较低的加重风险相关。玫瑰痤疮发作频繁会增加感染后加重风险（OR=8.288，95%CI：2.044-33.608）。总之，较低的BMI与新冠疫苗接种或感染后玫瑰痤疮加重的较高风险相关。有灼痛和刺痛症状或非丘疹脓疱型亚型的患者在接种疫苗后更易出现加重。
